Literature DB >> 18677519

Prognostic value of procalcitonin in Legionella pneumonia.

J Haeuptle1, R Zaborsky, R Fiumefreddo, A Trampuz, I Steffen, R Frei, M Christ-Crain, B Müller, P Schuetz.   

Abstract

The diagnostic reliability and prognostic implications of procalcitonin (PCT) (ng/ml) on admission in patients with community-acquired pneumonia (CAP) due to Legionella pneumophila are unknown. We retrospectively analysed PCT values in 29 patients with microbiologically proven Legionella-CAP admitted to the University Hospital Basel, Switzerland, between 2002 and 2007 and compared them to other markers of infection, namely, C-reactive protein (CRP) (mg/l) and leukocyte count (10(9)/l), and two prognostic severity assessment scores (PSI and CURB65). Laboratory analysis demonstrated that PCT values on admission were >0.1 in over 93%, >0.25 in over 86%, and >0.5 in over 82% of patients with Legionella-CAP. Patients with adverse medical outcomes (59%, n = 17) including need for ICU admission (55%, n = 16) and/or inhospital mortality (14%, n = 4) had significantly higher median PCT values on admission (4.27 [IQR 2.46-9.48] vs 0.97 [IQR 0.29-2.44], p = 0.01), while the PSI (124 [IQR 81-147] vs 94 [IQR 75-116], p = 0.19), the CURB65 (2 [IQR 1-2] vs 1 [1-3], p = 0.47), CRP values (282 [IQR 218-343], p = 0.28 vs 201 [IQR 147-279], p = 0.28), and leukocyte counts (12 [IQR 10-21] vs 12 [IQR 9-15], p = 0.58) were similar. In receiver operating curves, PCT concentrations on admission had a higher prognostic accuracy to predict adverse outcomes (AUC 0.78 [95%CI 0.61-96]) as compared to the PSI (0.64 [95%CI 0.43-0.86], p = 0.23), the CURB65 (0.58 [95%CI 0.36-0.79], p = 0.21), CRP (0.61 [95%CI 0.39-0.84], p = 0.19), and leukocyte count (0.57 [95%CI 0.35-0.78], p = 0.12). Kaplan-Meier curves demonstrated that patients with initial PCT values above the optimal cut-off of 1.5 had a significantly higher risk of death and/or ICU admission (log rank p = 0.003) during the hospital stay. In patients with CAP due to Legionella, PCT levels on admission might be an interesting predictor for adverse medical outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677519     DOI: 10.1007/s10096-008-0592-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

1.  Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings.

Authors:  Matti Korppi; Sami Remes; Tarja Heiskanen-Kosma
Journal:  Pediatr Pulmonol       Date:  2003-01

2.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

3.  Legionella pneumonia and serum procalcitonin.

Authors:  Laura Franzin; Daniela Cabodi
Journal:  Curr Microbiol       Date:  2004-10-28       Impact factor: 2.188

4.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

Authors:  Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller
Journal:  Am J Respir Crit Care Med       Date:  2006-04-07       Impact factor: 21.405

Review 5.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.

Authors:  Benjamin M P Tang; Guy D Eslick; Jonathan C Craig; Anthony S McLean
Journal:  Lancet Infect Dis       Date:  2007-03       Impact factor: 25.071

6.  Meta-analysis of procalcitonin for sepsis detection.

Authors:  Beat Müller; Mirjam Christ-Crain; Philipp Schuetz
Journal:  Lancet Infect Dis       Date:  2007-08       Impact factor: 25.071

7.  Procalcitonin increase in early identification of critically ill patients at high risk of mortality.

Authors:  Jens Ulrik Jensen; Lars Heslet; Tom Hartvig Jensen; Kurt Espersen; Peter Steffensen; Michael Tvede
Journal:  Crit Care Med       Date:  2006-10       Impact factor: 7.598

8.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

9.  Procalcitonin and neopterin correlation with aetiology and severity of pneumonia.

Authors:  Cristina Prat; Josep Domínguez; Felipe Andreo; Silvia Blanco; Angeles Pallarés; Federico Cuchillo; Carmen Ramil; Juan Ruiz-Manzano; Vicente Ausina
Journal:  J Infect       Date:  2005-07-18       Impact factor: 6.072

10.  Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.

Authors:  Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller
Journal:  BMC Health Serv Res       Date:  2007-07-05       Impact factor: 2.655

View more
  12 in total

1.  Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Derek N Bremmer; Briana E DiSilvio; Crystal Hammer; Moeezullah Beg; Swati Vishwanathan; Daniel Speredelozzi; Matthew A Moffa; Kurt Hu; Rasha Abdulmassih; Jina T Makadia; Rikinder Sandhu; Mouhib Naddour; Noreen H Chan-Tompkins; Tamara L Trienski; Courtney Watson; Terrence J Obringer; Jim Kuzyck; Thomas L Walsh
Journal:  J Gen Intern Med       Date:  2018-02-05       Impact factor: 5.128

Review 2.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

3.  Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia.

Authors:  Rosa Bellmann-Weiler; Mathias Ausserwinkler; Katharina Kurz; Igor Theurl; Guenter Weiss
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

4.  Pneumococcal and Legionella Urinary Antigen Tests in Community-acquired Pneumonia: Prospective Evaluation of Indications for Testing.

Authors:  Shawna Bellew; Carlos G Grijalva; Derek J Williams; Evan J Anderson; Richard G Wunderink; Yuwei Zhu; Grant W Waterer; Anna M Bramley; Seema Jain; Kathryn M Edwards; Wesley H Self
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

5.  Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.

Authors:  Philipp Schuetz; Marcel Wolbers; Mirjam Christ-Crain; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Thomas Fricker; Claudine Blum; Ursula Schild; Nils G Morgenthaler; Ronald Schoenenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Mueller
Journal:  Crit Care       Date:  2010-06-08       Impact factor: 9.097

Review 6.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

Authors:  Philipp Schuetz; Werner Albrich; Beat Mueller
Journal:  BMC Med       Date:  2011-09-22       Impact factor: 8.775

Review 7.  Systematic review regarding metabolic profiling for improved pathophysiological understanding of disease and outcome prediction in respiratory infections.

Authors:  Manuela Nickler; Manuel Ottiger; Christian Steuer; Andreas Huber; Janet Byron Anderson; Beat Müller; Philipp Schuetz
Journal:  Respir Res       Date:  2015-10-15

8.  Procalcitonin is not an independent predictor of 30-day mortality, albeit predicts pneumonia severity in patients with pneumonia acquired outside the hospital.

Authors:  Takanori Akagi; Nobuhiko Nagata; Hiroyuki Miyazaki; Taishi Harada; Satoshi Takeda; Yuji Yoshida; Kenji Wada; Masaki Fujita; Kentaro Watanabe
Journal:  BMC Geriatr       Date:  2019-01-07       Impact factor: 3.921

Review 9.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

Review 10.  Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.

Authors:  Dan Liu; Long-Xiang Su; Wei Guan; Kun Xiao; Li-Xin Xie
Journal:  Respirology       Date:  2015-12-10       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.